SCHEMBL18003995

SCHEMBL18003995

N#Cc1[nH]nnc1-c1cccc(OCc2ccc(F)c(F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.43
F9 P00740 1/20 0.42
F10 P00742 1/20 0.42
CNR1 P21554 5/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
PPARG P37231 1/20 0.40
KMT2A Q03164 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
ADORA2A P29274 1/20 0.40
ALOX5 P09917 1/20 0.38
CYP11B1 P15538 3/20 0.38
CNR2 P34972 1/20 0.38
CYP11B2 P19099 1/20 0.38
APLNR P35414 1/20 0.37
FFAR1 O14842 1/20 0.37
MAOB P27338 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18004424 0.87 FFAR1 (0.39) KDM4EMEN1ALDH1A1MAPTPPARG
SCHEMBL18004188 0.87 USP7 (0.39) IGF1RF9F10KDM4EMEN1
SCHEMBL18005970 0.86 NR4A2 (0.46) IGF1RF9F10CNR1KDM4E
SCHEMBL18004190 0.86 CNR1 (0.44) F9F10CNR1CNR2MAOB
SCHEMBL18004433 0.85 NR4A2 (0.47) IGF1RCYP11B1CYP11B2MAOBMAOA
SCHEMBL18006259 0.85 MAOB (0.45) IGF1RKDM4EMEN1ALDH1A1MAPT
SCHEMBL18004208 0.85 EGFR (0.39) IGF1RKDM4EMEN1ALDH1A1MAPT
SCHEMBL18006432 0.85 CYP11B1 (0.51) KDM4EMEN1ALDH1A1MAPTPPARG
SCHEMBL18004480 0.85 MEN1 (0.41) IGF1RKDM4EMEN1ALDH1A1MAPT
SCHEMBL18005947 0.85 NAAA (0.47) IGF1RCYP11B1MAOBNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 IGF1R 606/4885F9 3980/4885F10 3774/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 IGF1R 606/4885F9 3980/4885F10 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.